

**The YODA Project
Research Proposal Due Diligence Assessment**

Part 1: General Information	
YODA Project (Protocol) ID:	2018-3745
Date:	7 December 2018
Product Name:	Abiraterone acetate
Therapeutic Area:	Oncology
Product Class:	CYP17 inhibitor
Condition(s) Studied:	Prostatic Neoplasms
Protocol Number(s) and Title(s):	<p>NCT00638690/ COU-AA-301 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy</p> <p>NCT00887198/COU-AA-302- A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer</p>
Part 2: Data Availability	
Question:	Response:
Data Partner has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments:	
Data Partner has shareable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments:	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments:	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments:	
Data Partner has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments:	
Part 3: Data Availability Summary	
Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.	Yes
Part 4: Proposal Review	
Question:	Response:
Summary-level CSR data is appropriate for the proposed analysis.	No
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	No
Comments:	